Logo

Sema4 Signs a Definitive Agreement to Acquire GeneDx for ~$623M

Share this
Sema4 Signs a Definitive Agreement to Acquire GeneDx for ~$623M

Sema4 Signs a Definitive Agreement to Acquire GeneDx for ~$623M

Shots:

  • Sema4 will acquire GeneDx for a total consideration of ~$623M including $150M up front in cash, 80.0M shares in Sema4's common stock (~$473M as total upfront), ~$150M revenue-based milestones for a next 2 yrs. The combined company is expected to provide $350M in pro forma 2022 revenue
  • Sema4 also entered into agreements for a $200M private placement in Class A common stock at $4.00/share from Pfizer & institutional investors. The transaction is expected to close in Q2’22,
  • The acquisition strengthens Sema4’s AI-driven genomic & clinical data intelligence platform & add GeneDx’s database of clinical exomes & annotated phenotypes to Sema4’s platform to enable precision medicine to patients

Ref: Sem4 | Image: HIT Consultant

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions